Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 2Weight Loss 1Triple Negative Breast Neoplasms 1Thrombocytopenia 1Splenomegaly 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Fever 1Fatigue 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Anemia 1Advanced Breast Cancer 1

Interventions

Fulvestrant 4palbociclib 3Letrozole 3Paclitaxel 2sonidegib 1ribociclib 1irinotecan sucrosofate 1elacestrant 1XMT-1522 1Vorinostat 1Sirolimus 1Ritonavir 1Population Groups 1Itraconazole 1Immunotherapy, Adoptive 1Histone Deacetylase Inhibitors 1FCN-437c 1Docetaxel 1Decitabine 1Dasatinib 1Combined Modality Therapy 1Capecitabine 1CYH33 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Breast Cancer × Ritonavir × Clear all
NCT06710990 2026-06-04

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
17 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡